A Single Centre Experience of Clinically Suspected Myelodysplastic Syndrome Cohort
Asian Hematology Research Journal,
Purpose: 1. To study clinical, histo-morphological and cytogenetic profile of clinically suspected MDS cases. 2. Categorisation according to recent WHO classification, IPSS-R scoring and clinical outcome.
Methods: This was a retrospective study conducted over a period of 2 years from Jan 2019 to Dec 2020. Laboratory received blood, bone marrow aspirate and biopsy samples with clinical diagnosis of MDS was reviewed in correlation with outsourced cytogenetic study reports in Haematology laboratory services department, Apollo Hospitals Bannerghatta road, Bengaluru.
Results: Based on WHO criteria, out of 50 cases, eight cases belonged to category ICOUS, and 7 cases fell into others. Out of the 35 cases, MDS EB-2 was noted in 23% of the cases. 25 cases were sent for cytogenetic study and 7 were positive. One case was positive for Monosomy 7, 2 for Trisomy 8, 4 for 5q deletion, and one of it had 5q deletion with trisomy 8. Packed red blood cells (PRBC) was transfused in 11 patients. Decitabine was the commonest hypomethylating agent given in 10 patients followed by lenalidomide in 5 patients. Out of 11 MDS EB-1 and MDS EB-2 cases, four patient died and both categories showed statistically significant risk of association between disease and poor outcome.
Conclusion: MDS EB-1 and EB-2 was the second commonest WHO category collaterally having the highest IPSS-R score and worst prognosis. 5q deletion was the commonest cytogenetic abnormality seen.
- myelodysplastic syndrome
- risk stratification
How to Cite
Germing U, Kobbe G, Haas R. Gatter-mann N: Myelodysplastic syndromes: Diagnosis, prognosis and treatment. Dtsch Arztebl Int. 2013;110(46):783–90.
Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. The American Journal of Medicine. 2012; 125(7):6-13.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds.) WHO Classification of tumours of haematopoietic and lymphoid tissues, revised 4th ed, IARC: Lyon, France; 2017.
Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, riskstratification and management. Am J Hematol. 2018;93: 129–147.
Rakhee Kar, Seema Rao & Renu Saxena. Myelodysplastic syndromes: Classification and prognostic scoring systems and their applicability in Indian scenario-experience from a tertiary care centre. Hematology. 2009:14(3):145-149.
Rameshkumar K, Arumugam M, Samaga LN, Shetty P, Shetty J. Myelodysplastic syndrome among elderly patients with anemia: A Single institutional experience. J Appl Hematol. 2018;9:63-7.
Shah NM, Prajapati SG, Adesara RP, Patel AP. An analysis of 30 cases of myelodysplastic syndrome. Indian Journal of Pathology and Microbiology. 2009:52(2):206-209.
Steensma PD. Myelodysplastic syndromes current treatment algorithm. Blood Cancer Journal. 2018:8:47,1-7.
Abdel WR, AL- Haliq AR, Khasawneh R, Al-Momani A, Aladily TN. Myelody- splastic syndromes in jordan: A study form a large center. Int J Biol Med Res. 2012;3(2):1525-1528.
Mona Bargotya, Ankita Mehta, Sarjana Dutt, Harsh Dua, Tejinder Singh. Myelodysplastic syndrome (mds) with isolated 5q deletion ((5q – Syndrome): Report of two cases with review of literature. World J Pathol. 2018;7:1-6.
Chaubey R, Sazawal S, Dada R, Mahapatra M, et al. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res. 2011;134:452-457.
Abstract View: 55 times
PDF Download: 25 times